Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302)

BACKGROUND: Abiraterone acetate (an androgen biosynthesis inhibitor) plus prednisone is approved for treating patients with metastatic castration-resistant prostate cancer (mCRPC). Study COU-AA-302 evaluated abiraterone acetate plus prednisone versus prednisone alone in mildly symptomatic or asympto...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Eur Urol
Главные авторы: Rathkopf, Dana E., Smith, Matthew R., de Bono, Johann S., Logothetis, Christopher J., Shore, Neal D., de Souza, Paul, Fizazi, Karim, Mulders, Peter F.A., Mainwaring, Paul, Hainsworth, John D., Beer, Tomasz M., North, Scott, Fradet, Yves, Van Poppel, Hendrik, Carles, Joan, Flaig, Thomas W., Efstathiou, Eleni, Yu, Evan Y., Higano, Celestia S., Taplin, Mary-Ellen, Griffin, Thomas W., Todd, Mary, Yu, Margaret, Park, Youn C., Kheoh, Thian, Small, Eric J., Scher, Howard I., Molina, Arturo, Ryan, Charles J., Saad, Fred
Формат: Artigo
Язык:Inglês
Опубликовано: 2014
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4418928/
https://ncbi.nlm.nih.gov/pubmed/24647231
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2014.02.056
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы